Thomas Civik's most recent trade in Pyxis Oncology Inc was a trade of 2,503,050 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Sept. 4, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Pyxis Oncology Inc | Mr. Thomas Civik | Director, CEO & Chairman of the Board | 04 Sep 2026 | 2,503,050 | 2,503,050 | - | - | Stock Option (Right to Buy) | ||
| Pyxis Oncology Inc | Mr. Thomas Civik | Director, Interim CEO | 12 Aug 2026 | 250,956 | 941,087 | - | - | Stock Option (Right to Buy) | ||
| Pyxis Oncology Inc | Mr. Thomas Civik | Director, Interim CEO | 03 Feb 2026 | 690,131 | 690,131 | - | - | Stock Option (Right to Buy) | ||
| Pyxis Oncology Inc | Mr. Thomas Civik | Director | 31 Mar 2025 | 36,979 | 36,979 | - | - | Stock Option (Right to Buy) | ||
| Repare Therapeutics Inc | Thomas Civik | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2024 | 27,200 | 27,200 | - | - | Stock Option (right to buy) | |
| Pyxis Oncology Inc | Mr. Thomas Civik | Director | 26 Mar 2024 | 44,024 | 44,024 | - | - | Stock Option (Right to Buy) | ||
| Repare Therapeutics Inc | Thomas Civik | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2023 | 27,200 | 27,200 | - | - | Stock Option (right to buy) | |
| Pyxis Oncology Inc | Mr. Thomas Civik | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2023 | 139,355 | 206,186 | - | 0 | Common Stock | |
| Repare Therapeutics Inc | Thomas Civik | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2022 | 49,000 | 49,000 | - | - | Stock Option (right to buy) | |
| Pyxis Oncology Inc | Mr. Thomas Civik | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2022 | 66,831 | 66,831 | - | 0 | Common Stock | |
| Pyxis Oncology Inc | Mr. Thomas Civik | Director | Purchase of securities on an exchange or from another person at price $ 12.74 per share. | 18 Nov 2021 | 15,700 | 15,700 | - | 12.7 | 200,018 | Common Stock |
| Repare Therapeutics Inc | Thomas Civik | Director | Purchase of securities on an exchange or from another person at price $ 28.08 per share. | 16 Nov 2021 | 7,500 | 7,500 | - | 28.1 | 210,600 | Common Shares |